---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-036359"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2022-03-22T23:59:59+00:00"
generated_at: "2026-06-26T21:09:31.834638+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma FY2021 net loss $12.9M; IPO raised $16M; CFO replaced

## Summary
- Net loss of $12.9M for FY2021, including $7.0M upfront license payments and $1.9M non-cash equity compensation.
- Cash and equivalents $5.7M at Dec 31, 2021; $16M gross IPO proceeds in Feb 2022 not included.
- Phase 1a trial for NXP800 (HSF1 inhibitor) initiated Dec 2021; IND-enabling studies for NXP900 ongoing.
- Michael Carson appointed VP of Finance, replacing interim CFO Uri Ben-Or; Carson is a CPA with biotech finance experience.

## SEC filing metadata
- accession: 0001104659-22-036359
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2022-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465922036359/0001104659-22-036359-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465922036359/tm229925d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-036359
- JSON: https://secwatch.observer/filing/0001104659-22-036359.json
- Plain text: https://secwatch.observer/filing/0001104659-22-036359.txt

## Key facts
- Executive change
  Michael Carson was appointed as Vice President of Finance at Nuvectis Pharma, Inc..
  - Action: appointed
  - Role: Vice President of Finance
  source text: Michael Carson, who recently joined Nuvectis as Vice President of Finance, is replacing Uri Ben-Or
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465922036359/0001104659-22-036359-index.htm
- Executive change
  Uri Ben-Or departed as Interim Chief Financial Officer at Nuvectis Pharma, Inc..
  - Action: replaced
  - Role: Interim Chief Financial Officer
  source text: Uri Ben-Or who served as the Company's Interim Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465922036359/0001104659-22-036359-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.